Upgrade to SI Premium - Free Trial

Goldman Sachs: 'we expect GILD to continue to engage in strategic BD'

March 24, 2026 6:36 AM
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments